Jazz Pharmaceuticals plc (JAZZ)
Chart Events
Performance Outlook
| Previous Close | 153.72 |
| Open | 152.32 |
| Bid | 152.98 x 800 |
| Ask | 152.92 x 900 |
| Day's Range | 152.32 - 155.51 |
| 52 Week Range | 117.64 - 169.98 |
| Volume | |
| Avg. Volume | 512,880 |
| Market Cap | 9.615B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.37 |
| Earnings Date | Aug 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 201.82 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ
Related Research
- Jazz Pharmaceuticals plcAnalyst Report: Jazz Pharmaceuticals plcJazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.RatingFair ValueEconomic Moat26 days agoMorningstar
- Benzinga
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to $204 with a reiterated Buy rating on slightly increased forward EPS estimates. Jazz reported a thorough 2Q22 beat, with broad product outperformance vs. consensus across neuro and oncology, plus gross margin upside and light OPEX, HC Wainwright notes. As per the analyst, this looked to be Jazz’s second-biggest operating cash flow quarter ever, pushing net leverage down to 3.2x, six months ahead of the targeted
- Zacks
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
- Zacks
Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.
